The European Medicines Agency and European Commission are jointly developing Enhertu for market approval and seeking authorization in the EU.
2 reports, 1 independent
Updated Jul 24
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The European Medicines Agency and European Commission are jointly developing Enhertu for market approval and seeking authorization in the EU.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
European Medicines Agency
highest regulatory authority on medicines in the European Union
-
European Commission
executive branch of the European Union
-
Daiichi Sankyo
Japanese pharmaceutical company
-
AstraZeneca
British-Swedish pharmaceutical company
Related events
- AbbVie submitted an application for risankizumab approval to the European Medicines Agency.
- Oncopeptides AB's drug received a positive opinion from the EMA, leading to the European Commission making a final decision for the EU market.
- INmune Bio Inc. submitted an Orphan Drug Designation and Scientific Advice package to the European Medicines Agency.
- Both the FDA and the European Medicines Agency govern drug approval processes.
- Citigroup involved in global financial markets; India and Canada aiming to close CEPA trade pact; Biocon arm seeks EMA CHMP approval for drug.